↑ 薬物リストへ　← 戻る

Zilucoplan (ra101495)    (DrugBank: Zilucoplan)

3 diseases
告示番号疾患名（ページ内リンク）臨床試験数
2筋萎縮性側索硬化症0
11重症筋無力症3
62発作性夜間ヘモグロビン尿症3

2. 筋萎縮性側索硬化症　［臨床試験数：508，薬物数：530（DrugBank：146），標的遺伝子数：170，標的パスウェイ数：221］
Searched query = "Amyotrophic lateral sclerosis", "ALS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: . Trials are sorted by Date_enrollment from most recent to oldest in the table.
0 / 508 trial found

11. 重症筋無力症　［臨床試験数：226，薬物数：172（DrugBank：45），標的遺伝子数：43，標的パスウェイ数：118］
Searched query = "Myasthenia", "MG"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 226 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT04225871
(ClinicalTrials.gov)		December 23, 20192/10/2019Open-Label Extension of Zilucoplan in Subjects With Generalized Myasthenia GravisA Phase 3, Multicenter, Open-Label Extension Study of Zilucoplan in Subjects With Generalized Myasthenia GravisGeneralized Myasthenia GravisDrug: zilucoplan (RA101495)Ra PharmaceuticalsNULLRecruiting18 YearsN/AAll200Phase 3United States;Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom
2NCT04115293
(ClinicalTrials.gov)		October 1, 20192/10/2019Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisA Phase 3, Multicenter, Randomized, Double Blind, Placebo-Controlled Study to Confirm the Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia GravisMyasthenia Gravis, GeneralizedDrug: zilucoplan (RA101495);Drug: PlaceboRa PharmaceuticalsNULLRecruiting18 Years75 YearsAll130Phase 3United States;Canada;France;Germany;Italy;Japan;Norway;Spain;United Kingdom
3NCT03315130
(ClinicalTrials.gov)		October 11, 201716/10/2017Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia GravisA Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects With Generalized Myasthenia GravisGeneralized Myasthenia GravisDrug: zilucoplan (RA101495);Drug: PlaceboRa PharmaceuticalsNULLActive, not recruiting18 Years85 YearsAll44Phase 2United States;Canada

62. 発作性夜間ヘモグロビン尿症　［臨床試験数：202，薬物数：120（DrugBank：25），標的遺伝子数：15，標的パスウェイ数：90］
Searched query = "Paroxysmal nocturnal hemoglobinuria", "PNH"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
3 / 202 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT03225287
(ClinicalTrials.gov)		July 17, 201717/7/2017Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical StudyA Multicenter, Open-label, Uncontrolled, Extension Study of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have Completed a RA101495 Clinical StudyParoxysmal Nocturnal Hemoglobinuria (PNH)Drug: Zilucoplan (RA101495)Ra PharmaceuticalsNULLActive, not recruiting18 YearsN/AAll28Phase 2United States;Australia;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom
2NCT03030183
(ClinicalTrials.gov)		April 17, 201720/1/2017Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to EculizumabA Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to EculizumabParoxysmal Nocturnal Hemoglobinuria (PNH)Drug: Zilucoplan (RA101495)Ra PharmaceuticalsNULLCompleted18 YearsN/AAll3Phase 2United States
3NCT03078582
(ClinicalTrials.gov)		March 8, 20178/3/2017Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH PatientsPhase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal HemoglobinuriaParoxysmal Nocturnal Hemoglobinuria (PNH)Drug: Zilucoplan (RA101495)Ra PharmaceuticalsNULLCompleted18 YearsN/AAll26Phase 2Australia;Canada;Denmark;Finland;Germany;Hungary;New Zealand;United Kingdom

先頭へ